Biological Trace Element Research

, Volume 130, Issue 3, pp 262–272 | Cite as

Chromium Chloride Administration Causes a Substantial Reduction of Coronary Lipid Deposits, Aortic Lipid Deposits, and Serum Cholesterol Concentration in Rabbits

  • David A. Price Evans
  • Mohammad Tariq
  • Rofaida Dafterdar
  • Hussa Al Hussaini
  • Samia H. Sobki
Article

Abstract

This experiment was carried out to test the null hypothesis that intramuscular trivalent chromium administration would not remove lipids from the heart and ascending aorta of the hyoercholesterolemic rabbits and would not lower their serum cholesterol levels. A novel computer-based method, previously described, was used to assess the sizes of the intracardiac and aortic lesions. Clinical chemistry and histopathology were performed through routine methods. The sizes of the lipid deposits in the coronary vasculature of the hypercholesterolemic rabbits were greatly reduced as a result of the intramuscular chromium chloride injections. Lipid deposits in the ascending aorta were similarly reduced, as well as the serum cholesterol concentrations. The terminal serum chromium concentrations in the chromium-treated group were in the range of 3,258–4,513 μg/L, whereas, in the untreated animals, the concentrations were 3.2 to 6.3 μg/L. The general condition of the chromium-treated animals was good and they were continuing to gain weight up to the time they were killed. However, it was found that their liver function tests had become abnormal even though there was no evidence of hepatic histopathological lesions specifically affecting the chromium-treated group. The kidney function tests and histopathology were normal. These findings suggest that a more aggressive approach than those tried hitherto might be useful in treating atherosclerotic human patients with chromium.

Keywords

Hypercholesterolemic rabbit Cardiac atherosclerosis Parenteral trivalent chromium 

References

  1. 1.
    Vincent JB. Recent advances in the nutritional biochemistry of trivalent chromium. Proceedings of the Nutritional Society. 63, 41–47 (2004)Google Scholar
  2. 2.
    Anderson RA, Bryden NA, Polansky MM. Lack of toxicity of chromium chloride and chromium picolinate in rats. Journal of the American College of Nutrition. 16, 273–279 (1997)PubMedGoogle Scholar
  3. 3.
    Baruthio F Toxic effects of chromium and it’s compounds Biologcal Trace Element Research. 32, 145–153 (1992)CrossRefGoogle Scholar
  4. 4.
    Abraham AS, Brooks BA, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism. 41, 758–771 (1992)CrossRefGoogle Scholar
  5. 5.
    Bahijiri SM, Mira SA, Mufti AM. The effects of inorganic chromium and brewer’s yeast supplementation on glucose tolerance test,serum lipids and drug dosage in individuals with type 2 diabetes. Saudi Medical Journal. 21, 831–837 (2000)PubMedGoogle Scholar
  6. 6.
    Vinson JA, Mandarano MA, Shuta DL, Bagchi M, Bagchi D. Beneficial effects of novel IH636 Grape seed proanthocyanidin extract and niacin-bound chromium in a hamster atherosclerosis model. Molecular & Cellular Biochemistry. 240, 99–103 (2002)CrossRefGoogle Scholar
  7. 7.
    Rabinovitz H, Friedsohn A, Leibovitz A, Gabay G, Rocas C, Habot B. The effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients. International Journal for Vitamin and Nutritional Research. 74, 178–182 (2004)CrossRefGoogle Scholar
  8. 8.
    Yang X, Li S-T, Dong F, Ren J, Sreejayan N. Insulin-sensitizing and cholesterol-lowering effects of chromium(D-phenylalaninine) Journal of Inorganic Biochemistry. 100, 1187–1193 (2006)PubMedCrossRefGoogle Scholar
  9. 9.
    Atac IA, Peksel A, Yanardag B, Sonken BB, Doger MM, Bilen ZG. The effect of combined treatment with niacin and chromium (III) chloride on the different tissues of hyperlipemic rats. Drug and Chemical Toxicology. 29, 363–377 (2006)PubMedCrossRefGoogle Scholar
  10. 10.
    Broadhurst CL, Domenico P. Clinical studies on chromium picolinate. Diabetes Technology & Therapeutics. 8, 677–687 (2006)CrossRefGoogle Scholar
  11. 11.
    Geohas J, Daly A, Juturu V, Finch M, Komorowski J. Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: A placebo-controlled, double-blinded, randomized clinical trial. American Journal of Medical Sciences. 333, 145–153 (2007)CrossRefGoogle Scholar
  12. 12.
    Kleefstra N, Houweling ST, Jansman FGA, Groenier KH, Gans ROB, Jong BM, Bakker SJL. Chromium treatment has no effect in patients with poorly controlled, insulin-treated Type 2 diabetes in an obese Western population, Diabetes Care. 29, 521–525 (2006)PubMedCrossRefGoogle Scholar
  13. 13.
    Ghosh D, Bhattacharya B, Mukherjee B, Manna B, Sinha M, Chowdhury J, Chowdhury S. Role of chromium supplementation in Indians with type 2 diabetes mellitus. The Journal of Nutritional Biochemistry. 13, 690–697 (2002)PubMedCrossRefGoogle Scholar
  14. 14.
    Staub HW, Reussner G, Thiessen R. Serum cholesterol reduction by chromium in hypercholesterolemic rabbits. Science. 166, 746–747 (1969)PubMedCrossRefGoogle Scholar
  15. 15.
    Schroeder HA, Balassa JJ. Influence of chromium, cadmium and lead on rat aortic lipids and circulating cholesterol. American Journal of Physiology. 209, 433–437 (1965)PubMedGoogle Scholar
  16. 16.
    Abraham AS, Brooks BA, Eylathu U. Chromium and cholesterol-induced atherosclerosis in rabbits. Annals of Nutrition and Metabolism. 35, 203–207 (1991)PubMedCrossRefGoogle Scholar
  17. 17.
    Finking G, Hanke H. Nikolaj Nicolajewitsch Anitschow (1885–1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis Research. 35, 1–7 (1997)CrossRefGoogle Scholar
  18. 18.
    Shiomi M, Ito T, Tsukada T, Yata T, Ueda M. Cell compositions of coronary and aortic atherosclerotic lesions in WHHL rabbits differ—an immunological study. Atherosclerosis and Thrombosis. 14, 931–937 (1994)Google Scholar
  19. 19.
    Shiomi M, Ito T, Shirashi M, Watanabe Y. Inheritability of atherosclerosis and the role of lipoproteins as risk factors in the development of atherosclerosis in WHHLrabbits. Risk factors related to coronary atherosclerosis are different to those related to aortic atherosclerosis. Atherosclerosis. 96, 43–52 (1992)PubMedCrossRefGoogle Scholar
  20. 20.
    Ginsburg R, Davis K, Bristow MR, McKennett K, Kodsi SR, Billingham ME, Schroeder JS. Calcium antagonists suppress atherogenesis in aorta but not in intramural coronary arteries of cholesterol-fed rabbits. Laboratory Investigation. 49, 154–158 (1983)PubMedGoogle Scholar
  21. 21.
    Kitajima AS, Sakuma S, Uchinuno Y, Terano T, Miyazaki A, Hakamata H, Horiuchi S. Quantitative analyses of lesion areas of coronary atherosclerosis in cholesterol-fed rabbits. Journal of Veterinary Medical Science. 58, 855–860 (1996)PubMedGoogle Scholar
  22. 22.
    Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib—was it the molecule or the mechanism? Atherosclerosis Thrombosis and Vascular Biology. 27, 257–260 (2007)CrossRefGoogle Scholar
  23. 23.
    Pedersen TR, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Wilhelmsen L, Faergeman O, Strandberg TE, Cook TJ, Hagfelt T, Kjekhus J, Miettinen T, Olsson AG, Pyorala K, Wedel H on behalf of the Scandinavian Simvastatin Survival Study Group. Follow up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology. 86, 257–262 (2000)PubMedCrossRefGoogle Scholar
  24. 24.
    Ford I, Murray H, Packard CI, Shepherd J, Macfarlne PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine. 357, 1477–1486 (2007)PubMedCrossRefGoogle Scholar
  25. 25.
    Evans DAP, Tariq M, Morgan JS, Riley PJ, Sobki SH. A novel computer-based method for the measurement of the lipid “load” in the coronary vessels of rabbits. Journal of Pharmacological and Toxicological Methods. 56, 323–329 (2007)PubMedCrossRefGoogle Scholar
  26. 26.
    Bleibel W, Kim S, D’Silva K, Lemmer ER. Drug-induced liver injury: Review article. Digestive Diseases and Sciences. 52, 2463–2471 (2007)PubMedCrossRefGoogle Scholar
  27. 27.
    Clodfelder BJ, Gullick BM, Lukaski HC, Neggers Y, Vincent JB. Oral administration of the biomimetic [Cr3(O2CCH3)6(H2O)3]+ increases insulin sensitivity and improves blood plasma variables in healthy and type 2 diabetic rats. Journal of Biological Inorganic Chemistry. 10, 119–130 (2005)PubMedCrossRefGoogle Scholar
  28. 28.
    Albarracin C, Fuqua B, Geohas J, Finch M, Komorowski JR, Effect of chromium picolinate and biotin combination on coronary risk lipids and lipoproteins in subjects with non-LDL-C(> = 130 mg/dl)in type 2 diabetes mellitus. Arteriosclerosis, Thrombosis and Vascular Biology. 25, p255. E98–E99. (2005)Google Scholar
  29. 29.
    Waldo SW, Li YF, Buono C, Zhao B, Billings EM, Chang J, Kruth HS. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. American Journal of Pathology. 172, 1112–1126 (2008)PubMedCrossRefGoogle Scholar
  30. 30.
    Jenner A, Ren M, Rajendran R, Ning P, Huat TK, Watt K. Halliwell B. Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet. Free Radical Biology and Medicine. 42, 559–566 (2007)PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • David A. Price Evans
    • 1
  • Mohammad Tariq
    • 1
  • Rofaida Dafterdar
    • 2
  • Hussa Al Hussaini
    • 3
  • Samia H. Sobki
    • 2
  1. 1.The Research CentreRiyadh Military HospitalRiyadhKingdom of Saudi Arabia
  2. 2.Chemical Pathology Section, Central LaboratoryRiyadh Military HospitalRiyadhKingdom of Saudi Arabia
  3. 3.Histopathology Section, Central LaboratoryRiyadh Military HospitalRiyadhKingdom of Saudi Arabia

Personalised recommendations